Better Outcomes With LAIs; Adderall Supply Woes; Fewer Psychiatrists Take Medicare

Swapping out oral antipsychotics for long-acting injectable antipsychotics resulted in 48% fewer psychiatric hospitalizations, 47% fewer hospitalizations for schizophrenia, 44% fewer suicide attempts, and 37% fewer all-cause hospitalizations among a group of Hong Kong patients with schizophrenia. (JAMA Network Open)

5,500: that’s the estimated number of suicides that were avoided over a 14-year period after California invested in mental health programs using revenue generated from its millionaire tax. (PLOS One)

Teva Pharmaceutical is facing supply issues for some of its dextroamphetamine/amphetamine (Adderall) products. (Bloomberg)

The investigational treatment CY6463 helped increase cognition scores over 14 days of once-daily dosing in those with cognitive impairment associated with schizophrenia, Cyclerion Therapeutics announced.

While fewer and fewer psychiatrists were accepting Medicare from 2013 to 2019, the number of psychiatric mental health nurse practitioners treating Medicare beneficiaries more than doubled. (JAMA Network Open)

Among kids ages 9 to 10, there were no sex differences seen when looking at the prevalence of disordered eating behaviors. (JAMA Pediatrics)

Psychiatric facilities will see an additional $90 million in Medicare payments in 2023, thanks to the Centers for Medicare & Medicaid Services’ final rule for the Inpatient Psychiatric Facility Prospective Payment System. (Bloomberg)

A study of older adults with depression on escitalopram (Lexapro) found there were distinct alterations in network connectivity among circuits that were tied to feelings of apathy and poor treatment response. (JAMA Network Open)